Plan Development for Giving Teclistamab in the Outpatient Setting
Plan Development for Giving Teclistamab in the Outpatient Setting
Recruiting · NCT06251076 · Registry updated 2025-12-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Plan Development for Giving Teclistamab in the Outpatient Setting | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, refractory malignant neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 4 | 2025-12-10 | NCT06251076 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Janssen Inc. | 6 |
| University Health Network, Toronto | 417 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Princess Margaret Cancer Centre | Toronto | Canada | 145 |